[
  {
    "date": "2023-12-31",
    "symbol": "XRTX",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2023,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "001-40858",
    "entityregistrantname": "XORTX Therapeutics Inc.",
    "entitycentralindexkey": 1729214,
    "entityincorporationstatecountrycode": "A1",
    "entityaddressaddressline1": "3710 — 33rd Street NW",
    "entityaddresscityortown": "Calgary",
    "entityaddressstateorprovince": "AB",
    "entityaddresscountry": "CA",
    "entityaddresspostalzipcode": "T2L 2M1",
    "cityareacode": 403,
    "localphonenumber": "455-7727",
    "security12btitle": "Common Shares",
    "tradingsymbol": "XRTX",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityshellcompany": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entitycommonstocksharesoutstanding": 1998848,
    "contactpersonnelname": "James Fairbairn",
    "contactpersonnelemailaddress": "jfairbairn@xortx.com",
    "auditorfirmid": 995,
    "auditorname": "Smythe LLP",
    "auditorlocation": "Vancouver, Canada",
    "cashandcashequivalents": 3447665,
    "currenttradereceivables": 60711,
    "prepaidexpenses": 236966,
    "ifrsdeferredofferingcosts": 323441,
    "currentassets": 4068783,
    "contractpaymentsnoncurrent": 1200000,
    "intangibleassetsandgoodwill": 175254,
    "propertyplantandequipment": 23927,
    "assets": 5467964,
    "tradeandotherpayablestotradesuppliers": 283428,
    "currentleaseliabilities": 11510,
    "currentliabilities": 294938,
    "noncurrentderivativefinancialliabilities": 531000,
    "liabilities": 825938,
    "issuedcapital": 17056535,
    "otherreserves": 5468257,
    "obligationtoissuesharesone": 24746,
    "accumulatedothercomprehensiveincome": -52605,
    "retainedearnings": -17854907,
    "equityattributabletoownersofparent": 4642026,
    "equityandliabilities": 5467964,
    "researchanddevelopmentexpense": 2418715,
    "consultingwagesandbenefits": 1037558,
    "directorsfees": 179406,
    "investorrelations": 919490,
    "professionalfeesexpense": 514263,
    "generalandadministrativeexpense": 375505,
    "publiccompanycosts": 170184,
    "travelexpense": 170187,
    "amortizationofpropertyandequipment": 73062,
    "amortizationofintangibleassetsandgoodwill": 66632,
    "sharebasedpayments": 120984,
    "profitlossbeforetax": -6045986,
    "fairvalueofexpectedcreditloss": 3641403,
    "foreignexchangegainloss": -7025,
    "interestandotherexpenses": 253543,
    "profitloss": -2158065,
    "comprehensiveincome": -2158065,
    "basicearningslosspershare": -1.09,
    "dilutedearningslosspershare": -1.09,
    "weightedaverageshares": 1981734,
    "adjustedweightedaverageshares": 1981734,
    "equity": 17056535,
    "numberofsharesoutstanding": 1998848,
    "reclassificationofderivativewarrantliability": -318000,
    "increasedecreasethroughexerciseofwarrantsequity": 532181,
    "increasedecreaseinsharesthroughexerciseofwarrantsequity": 328777,
    "increasedecreasethroughsharebasedpaymenttransactions": -120984,
    "adjustmentsfordepreciationandamortisationexpense": 139694,
    "adjustmentsforsharebasedpayments": 120984,
    "adjustmentsforunrealisedforeignexchangelossesgains": -13634,
    "adjustmentsfordecreaseincreaseintradeaccountreceivable": 21041,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": 142654,
    "otheradjustmentsforwhichcasheffectsareinvestingorfinancingcashflow": -1194436,
    "cashflowsfromusedinoperatingactivities": -6583165,
    "purchaseofintangibleassetsclassifiedasinvestingactivities": 42052,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 4311,
    "cashflowsfromusedininvestingactivities": -46363,
    "proceedsfromexerciseofwarrants": 296,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 66089,
    "paymentsforshareissuecosts": 295251,
    "cashflowsfromusedinfinancingactivities": -361044,
    "effectofexchangeratechangesoncashandcashequivalents": 4041,
    "increasedecreaseincashandcashequivalents": -6986531,
    "proportionofownershipinterestinsubsidiary": 1,
    "usefullifemeasuredasperiodoftimepropertyplantandequipment": "P3Y",
    "estimatedlivesofintangibleassets": "P20Y",
    "currentannualinterestrateearnedondeposits": 0.0515,
    "cashonhand": 94999,
    "shorttermdepositsclassifiedascashequivalents": 3352666,
    "currentprepaidinsurance": 204302,
    "currentprepaymentoninvestorrelationsconferencesandservices": 25309,
    "currentprepaymentonadministrativeservicesandother": 7355,
    "currentprepaidexpenses": 236966,
    "additionsotherthanthroughbusinesscombinationsintangibleassetsotherthangoodwill": 42052,
    "royaltyamountreceived": 0.05,
    "commercialsaleofproduct": "P10Y",
    "royaltypayment": 0.015,
    "receiptofregulatoryapproval1": 100000,
    "issuanceofufrfcommonshare": 160783,
    "milestonepaymentreceiptofapproval": 500000,
    "licencefeeincome": 1000,
    "additionsotherthanthroughbusinesscombinationspropertyplantandequipment": 4311,
    "tradeandotherpayables": 195814,
    "currentaccruedexpensesandothercurrentliabilities": 87614,
    "othercurrentliabilities": 283428,
    "leaseliabilities": 11510,
    "cashoutflowforleases": 66089,
    "undiscountedoperatingleasepaymentstobepaid": 11628,
    "lesseeliabilityundiscountedexcessamount": -118,
    "numberofsharesissued": 1998848,
    "changesinwarrants": 1125210,
    "expired": -32318,
    "granted": 400000,
    "exercisepriceshareoptionsexcersied": 0.0009,
    "exercisepriceshareoptions1": 22.31,
    "exercisepriceshareoptionsgranted2019": 10.98,
    "exercisepriceofoutstandingshareoptions2019": 42.26,
    "descriptionofexpirydateoftemporarydifferencesunusedtaxlossesandunusedtaxcredits": "February 9, 2026",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P3Y1M24D",
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions201912": "P2Y1M6D",
    "exercisepriceshareoptionsgranted1": 2.9,
    "exercisepriceshareoptionsgranted123": 0.0009,
    "excersied1": -328777,
    "numberofsharesoutstanding15": 6377,
    "increasedecreasethroughexerciseofwarrantsequity11": 3714757,
    "expectedlife1": "P5Y",
    "descriptionofexpectedvolatilityshareoptionsgranted": 1,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0325,
    "expectedlife": "P5Y",
    "exercisepriceshareoptionsexpired11": 33.65,
    "changesinwarrantsvestedandexercisable": 89872,
    "exercisepriceshareoptionsvestedandexercisable": 16.54,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 14.76,
    "increasedecreaseinnumberofsharesoutstanding": 14669,
    "fairvaluereclassifiedfromreservesliabilities": 318000,
    "fairvalueadjustment": -3641403,
    "expensefromsharebasedpaymenttransactionswithemployees": 120984,
    "exercisepriceshareoptionsgranted20191": 9.09,
    "descriptionofriskfreeinterestrateshareoptionsgranted1": 0.0366,
    "wagesandbenefits1": 417810,
    "transfersofresearchanddevelopmenttoentityrelatedpartytransactions": 200229,
    "revenuefromrenderingofinformationtechnologyconsultingservices": 280000,
    "directorsremunerationexpense": 182675,
    "amountspayablerelatedpartytransactions": 6805,
    "wagesandsalaries": 974240,
    "keymanagementpersonnelcompensationsharebasedpayment": 77779,
    "keymanagementpersonnelcompensation": 1234694,
    "netlossforyear": -2158000,
    "statutorytaxrate": 0.27,
    "expectedincometaxrecovery": -583000,
    "nondeductiblepermanentdifferences": 45000,
    "temporarydifferences": -25000,
    "overunderprovidedinprioryears": -559000,
    "changeintaxassetsnotrecognized": 1122000,
    "shareissuerelatedcost1": 229000,
    "cumulativeeligiblecapital": 117000,
    "operatinglossescarriedforward": 4819000,
    "totaldeferredtaxassets": 5165000,
    "deferredtaxassetsnotrecognized": -5165000,
    "deferredtaxexpenseincomerecognisedinprofitorloss": 44000,
    "deferredtaxassetsnoncapitallosscarryforwards": 21561000,
    "financialinstrumentasmeasuredatfairvaluethroughprofitorlossatcarryingvalue": 3447665,
    "financialinstrumentasmeasuredatfairvaluethroughprofitorlossatfairvalue": 3447665,
    "accountpayableandaccruedliability": 283428,
    "financialliabilities": 294938,
    "cash": 36627,
    "accountspayableandaccruedliabilities.": 173068,
    "netexposure": -136441,
    "effectofchangeincurrency": -13644,
    "postemploymentbenefitexpensedefinedcontributionplans": 321000,
    "terminationbenefitsexpense": 321000,
    "activitiesrelatedtoclinicaltrialmanufacturing": 446000,
    "numberofoperatingsegment": 1,
    "paymentsoffindersfees": 132551,
    "percentageoffindersfeeoncertainsubscriptionstoqualifiedfinders": 0.05
  }
]